In the latest trading session, 0.9 million Akebia Therapeutics Inc. (NASDAQ:AKBA) shares changed hands as the company’s beta touched 0.77. With the company’s most recent per share price at $1.62 changed hands at -$0.02 or -1.22% at last look, the market valuation stands at $340.67M. AKBA’s current price is a discount, trading about -53.09% off its 52-week high of $2.48. The share price had its 52-week low at $0.78, which suggests the last value was 51.85% up since then. When we look at Akebia Therapeutics Inc.’s average trading volume, we note the 10-day average is 1.46 million shares, with the 3-month average coming to 1.66 million.
Analysts gave the Akebia Therapeutics Inc. (AKBA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKBA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Instantly AKBA was in red as seen in intraday trades today. With action 21.80%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 30.65%, with the 5-day performance at 21.80% in the green. However, in the 30-day time frame, Akebia Therapeutics Inc. (NASDAQ:AKBA) is 20.00% up. Looking at the short shares, we see there were 18.8 million shares sold at short interest cover period of 12.81 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need an upside of 75.08% from its recent market value. According to analyst projections, AKBA’s forecast low is 6 with 7 as the target high. To hit the forecast high, the stock’s price needs a -332.1% plunge from its current level, while the stock would need to soar -270.37% for it to hit the projected low.
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Data shows that the Akebia Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.25% over the past 6 months, a 32.14% in annual growth rate that is considerably higher than the industry average of 17.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.46%. The 2024 estimates are for Akebia Therapeutics Inc. earnings to increase by 13.10%.
AKBA Dividends
Akebia Therapeutics Inc. is expected to release its next quarterly earnings report on 2024-Nov-06.
Akebia Therapeutics Inc. (NASDAQ:AKBA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.17% of Akebia Therapeutics Inc. shares while 27.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 27.59%. There are 27.00% institutions holding the Akebia Therapeutics Inc. stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.6786% of the shares, roughly 11.64 million AKBA shares worth $11.87 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.526% or 9.28 million shares worth $9.46 million as of 2024-06-30.
